Business & Regulation

If pharma is to retain its reputation as an innovator, companies must be brave enough to explore new areas, new targets and new technologies.

Big pharma must be more agile if it wants to make the most of the revolutionary advances that will shape the next decade.

Is research into orphan diseases on the rise?

Who should pay for the disposal of unused medicines? Legal tussles continue over ‘drug takeback’ law in Californian county.

EMA’s pilot project continues. Is the future of regulation adaptive?

Who are the top 100 most influential people in drug development and manufacturing today?

Pathways designed to bring medicines to market faster in Europe are not delivering the goods

What is an endolysin? We spoke with Bjorn Herpers from the Regional Public Health Laboratory Kennemerland, Haarlem, in the Netherlands to find out.

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

Science and business: tenacious partners in a shaky marriage or eternally bound nonidentical twins?